

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**GUIDANCE EXECUTIVE (GE)**

**Consideration of consultation responses on review proposal**

**Review of TA212; Bevacizumab in combination with oxaliplatin and either 5-fluorouracil plus folinic acid or capecitabine for treating metastatic colorectal cancer**

This guidance was issued December 2010 with a review date of May 2013.

**Background**

At the GE meeting of 23 April 2013 it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

<b>Proposal put to consultees:</b>	The guidance should be transferred to the 'static guidance list'.
<b>Rationale for selecting this proposal</b>	There is no significant new evidence that is likely to lead to a change in the recommendations in TA212, and no directly relevant ongoing studies. Therefore it is appropriate that the guidance be transferred to the static list.

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

<b>Recommendation post consultation:</b>	The guidance should be transferred to the 'static guidance list'.
--	---

<b>Respondent</b>	<b>Response to proposal</b>	<b>Details</b>	<b>Comment from Technology Appraisals</b>
Bladder and Bowel Foundation		Please note that B&BF will not be taking part in this appraisal.	Comment noted.
National Cancer Research Institute  Royal College of Physicians  Royal College of Radiologists  Association of Cancer Physicians	Agree	Our experts support the proposal to move the guidance to the static list.	Comment noted.
Medicines and Healthcare Products Regulatory Agency	No comment	We have no comment for this appraisal.	Comment noted.

Respondent	Response to proposal	Details	Comment from Technology Appraisals
Royal College of Nursing	No comment	Feedback received from nurses working in this area of health suggest that there are no comments to submit on behalf of the Royal College of Nursing to inform on the review proposal of the above technology.	Comment noted.

**No response received from:**

<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Roche Products (bevacizumab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Beating Bowel Cancer</li> <li>• Black Health Agency</li> <li>• Bowel Cancer Information</li> <li>• Bowel Cancer UK</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Colostomy Association</li> <li>• Equalities National Council</li> <li>• Helen Rollason Heal Cancer Charity</li> <li>• IA (Ileostomy and Internal Pouch Support Group)</li> <li>• Independent Age</li> <li>• Independent Cancer Patients' Voice</li> <li>• Macmillan Cancer Support</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturers</u></p>
--	---

- Maggie's Centres
- Marie Curie Cancer Care
- Muslim Council of Britain
- Muslim Health Network
- Ostomy Lifestyle
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Teenage Cancer Trust
- Tenovus

#### Professional groups

- Association of Anaesthetists of Great Britain and Ireland
- Association of Coloproctology of Great Britain
- Association of Surgeons of Great Britain and Ireland
- Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland
- British Association for Services to the Elderly
- British Association of Surgical Oncology
- British Geriatrics Society
- British Institute of Radiology
- British Psychosocial Oncology Society (BPOS)
- British Society of Gastroenterology
- British Society of Urogenital Radiology
- Cancer Network Pharmacists Forum
- Cancer Research UK
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Pathologists
- Royal College of Surgeons
- Royal Pharmaceutical Society

- Accord Healthcare (fluorouracil, irinotecan, oxaliplatin)
- Actavis UK (irinotecan, oxaliplatin)
- Hospira (calcium folinate, fluorouracil, irinotecan, oxaliplatin)
- Medac UK (disodium folinate, fluorouracil, irinotecan, oxaliplatin)
- Merck Serono (tegafur with uracil)
- Pfizer (irinotecan, calcium folinate, calcium levofolinate)
- Roche Products (capecitabine)
- Sandoz (irinotecan)
- Sanofi (oxaliplatin)
- Teva UK (calcium folinate)
- Wockhardt UK (calcium folinate)

#### Relevant research groups

- Cochrane Colorectal Cancer Group
- Cochrane Upper Gastrointestinal and Pancreatic Diseases Group
- Health Research Authority
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Cancer Research Network
- National Institute for Health Research
- Research Institute for the Care of Older People

#### Assessment Group

- Assessment Group tbc
- National Institute for Health Research Health Technology Assessment Programme

#### Associated Guideline Groups

<ul style="list-style-type: none"> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers (SCoR)</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• United Kingdom Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS Havering CCG</li> <li>• NHS Sandwell &amp; West Birmingham CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• National Collaborating Centre For Cancer</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul>
--	---

**GE paper sign-off:** Helen Knight, Associate Director – Technology Appraisals Programme

**Contributors to this paper:**

Technical Lead: Linda Landells

Project Manager: Andrew Kenyon

17 June 2013